WELCOME TO HALBERD CORPORATION
Halberd Corporation is a fully reporting issuer under the Securities Exchange Act of 1934, listed under “HALB” on the OTC-BB Index.
Halberd Corporation has acquired exclusive licenses for patent-pending medications/medical procedures to develop cures for a significant number of the most debilitating and often fatal illnesses affecting mankind: Amyotrophic Lateral Sclerosis (ALS), Traumatic Brain Injury (TBI), Multiple Sclerosis (MS), Clinical Depression, Alzheimer’s Disease, Blood Sepsis, Atherosclerosis and Cancer.
We have developed an aggressive timetable to advance the development of these breakthrough technologies through laboratory, hospital, and clinical trials. In addition, we have initiated the development of potential patient trial application lists. Our management team has extensive experience and contacts in the medical/pharmaceutical fields as well as a demonstrated track record of launching new business ventures in a competitive environment.
Our extensive contacts in the medical/pharmaceutical industries will ensure that new developments will achieve maximum visibility and exposure to the market.
Transparency and accountability will continue to be ensured via regular issuance of technical progress reports, financials, and investor relations reports to maintain investor enthusiasm.
2009 – Dr. Felder develops the theories that make the Felder Doctrine. Patents written and submitted
December 2010 – PBI incorporated in Nevada
December 2010 – Assembled Board of Directors. includes the Doctor, two attorneys, and individuals previously holding officer positions for public companies.
January 2011 – Halberd Corporation, Inc. begins process of “going public”.
March 2012 – Dr. Mitchell Felder meets with Dr. Robert A. Kirken, Ph.D. Professor and Chair, Department of Biological Sciences at the University of Texas at El Paso (UTEP).
April 2012 – UTEP demonstrates data to support Proof of Concept: Selective Depletion of Small Reactive Molecules.
May 2012 – PBI and UTEP sign Collaborative Agreement: Aphaeresis Selective Depletion of Small Reactive Molecules and Pathogens that Involves a Novel Treatment of Brain Injury (TBI), Chronic Pain Syndrome, Fibromyalgia, Multiple Sclerosis, Amyotrophic, Lateral Sclerosis (ALS or Lou Gehrig’s disease), Blood Sepsis, Cancer, Heart Attacks and Strokes.
June 2012 – UTEP presents Scope of Work Agreement for the Pre-clinical Development of Halberd Corporation Therapeutic Strategies
July 2012 – PBI and UTEP sign Scope of Work Agreement. Halberd Corporation, Inc. receives a letter of intent from William Beaumont Army Medical Center (WBAMC) stating their desire to join the consortium with their primary expertise in animal and clinical testing
August 2012 – Mutual Non-Disclosure Agreement with UTEP, PBI, and US Army Clinical Investigation Regulatory Office (CIRO). Halberd Corporation, Inc. begins primary fundraising for laboratory development and clinical testing–targeting private consortiums, institutional funds, grants, strategic partnerships, and philanthropic donations. HALB opens on OTCBB at $1.01.
Our goal is to complete the development and bring to market potential medications/procedures that address a significant number of the most highly visible health issues currently afflicting mankind—Amyotrophic Lateral Sclerosis (ALS/Lou Gehrig’s Disease), Traumatic Brain Injury (TBI), Multiple Sclerosis (MS), Blood Sepsis, and Cancer. Halberd Corporation is in the process of developing targeted medicines and procedures and will prove out their superior efficacy in addressing these diseases and others through laboratory, hospital, and actual patient applications.
At the anticipated successful conclusion of the clinical trials, contact will be established with the leading worldwide pharmaceutical firms via publication in medical journals and by direct contact to establish their potential right to market and distribute Halberd technology products and procedures. If successful, Halberd Corporation will remain an advanced research and development (R&D) arm of the world’s large pharmaceutical firms.
Research Partnership with University of Texas
On May 9, 2012, Halberd Corporation entered into a research partnership agreement with the University of Texas at El Paso (UTEP). Pursuant to the terms of the Agreement, we are working together on a series of research and development programs around our sequential-dialysis technology in the areas of Cancer, Alzheimer’s Disease, Traumatic Brain Injury (TBI), Chronic Pain Syndrome, Fibromyalgia, Multiple Sclerosis, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig’s disease), Blood Sepsis, Heart Attacks and Strokes.